These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 20579137)

  • 1. Medical treatment of benign prostatic hyperplasia: physician and patient preferences and satisfaction.
    Emberton M
    Int J Clin Pract; 2010 Sep; 64(10):1425-35. PubMed ID: 20579137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.
    Wei JT; Miner MM; Steers WD; Rosen RC; Seftel AD; Pasta DJ; Carman WJ; Roehrborn CG;
    J Urol; 2011 Sep; 186(3):971-6. PubMed ID: 21791352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding patient and physician perceptions of benign prostatic hyperplasia in Asia Pacific, Latin America and the Commonwealth of Independent States: the Prostate Research on Behaviour and Education (PROBE) II survey.
    Ertel P; Adalig B; Demircan I; Lartey B; Manyak MJ
    Int J Clin Pract; 2016 Oct; 70(10):870-880. PubMed ID: 27774780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment choice for benign prostatic hyperplasia: a matter of urologist preference?
    Stoevelaar HJ; Van de Beek C; Casparie AF; McDonnell J; Nijs HG
    J Urol; 1999 Jan; 161(1):133-8. PubMed ID: 10037385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study].
    Fourcade RO; Picot MC; Gaudin AF; Texier N; Slama A
    Presse Med; 2007 May; 36(5 Pt 1):755-63. PubMed ID: 17329070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey.
    Emberton M; Marberger M; de la Rosette J
    Int J Clin Pract; 2008 Jan; 62(1):18-26. PubMed ID: 18028388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving therapeutic outcomes in BPH through diagnosis, treatment and patient compliance.
    DeCastro J; Stone B
    Am J Med; 2008 Aug; 121(8 Suppl 2):S27-33. PubMed ID: 18675614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in initial benign prostatic hyperplasia management between primary care physicians and urologists.
    Hollingsworth JM; Hollenbeck BK; Daignault S; Kim SP; Wei JT
    J Urol; 2009 Nov; 182(5):2410-4. PubMed ID: 19765742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benign prostatic hyperplasia: a review.
    Ramsey EW
    Can J Urol; 2000 Dec; 7(6):1135-43. PubMed ID: 11151094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
    Seftel A; Rosen R; Kuritzky L
    Int J Impot Res; 2007; 19(4):386-92. PubMed ID: 17377613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Watchful waiting in benign prostatic hyperplasia.
    Wiygul J; Babayan RK
    Curr Opin Urol; 2009 Jan; 19(1):3-6. PubMed ID: 19057209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States.
    Gee WF; Holtgrewe HL; Albertsen PC; Litwin MS; Manyak MJ; O'Leary MP; Painter MR
    J Urol; 1995 Jul; 154(1):205-6. PubMed ID: 7539861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benign prostatic hyperplasia. Practical treatment guidelines.
    Tammela T
    Drugs Aging; 1997 May; 10(5):349-66. PubMed ID: 9143856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
    Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL
    Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey conducted on patients' and urologists' perceptions of benign prostatic hyperplasia.
    Kim SI; Kang JY; Lee HW; Seong do H; Cho JS
    Urol Int; 2011; 86(3):278-83. PubMed ID: 21273763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians.
    Sausville J; Naslund M
    Int J Clin Pract; 2010 Dec; 64(13):1740-5. PubMed ID: 21070524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of benign prostatic hyperplasia by family physicians.
    Toguri A; Barkin J
    Can J Urol; 2010 Feb; 17 Suppl 1():26-34. PubMed ID: 20170598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia.
    Llewellyn-Thomas HA; Williams JI; Levy L; Naylor CD
    Med Decis Making; 1996; 16(3):262-82. PubMed ID: 8818125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research.
    McConnell JD; Barry MJ; Bruskewitz RC
    Clin Pract Guidel Quick Ref Guide Clin; 1994 Feb; (8):1-17. PubMed ID: 7507389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.